Novel IVD antibodies are enriching clinical diagnostic and research applications focused on immuno-oncology.
FREMONT, CA: A leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, Biocare Medical, has launched 7 novel IVD IHC antibody markers for clinical diagnostics and research applications. The launched immuno-oncology markers are critical in aiding early-stage cancer drug developments, and patient treatment. The company re-developed a major antibody marker (S100 Protein) that is expressed in Schwannomas, ependymomas, astrogliomas, and nearly all melanomas (benign and malignant) and their metastases.
Biocare Medical is thrilled to launch novel, IVD IHC markers that meet the highest standards in cancer diagnostics. The new product recommence Biocare Medical's long-standing history of offering a novel, excellent reagents to customers looking to advance their research and diagnostic efficiency. Increasing the number of chronic diseases such as hepatitis, HIV, cardiovascular diseases, cancer, etc. is expected to fuel the growth of the market for IVD antibodies. The ease of use of IVD antibodies for the diagnosis at hospitals, laboratories, or even at home, further boosts patient compliance and makes IVD antibodies preferred choice.
Biocare Medical is a global pioneer in solutions for cancer research and diagnostics, offering excellent reagents, comprising tissue-conserving simultaneous multiplex antibody cocktails and detections, and a comprehensive suite of modern instrumentation for IHC, molecular, and histology testing. Consumers include clinical, pharmaceutical companies, anatomic pathology laboratories, CROs, and biotechnology organizations, and academic, military, government, and other non-profit laboratories. Biocare's reagent portfolio comprises Multiplex IHC, primary antibodies, and FISH probes for target indications. Biocare also provides a unique line of polymer detections for human, clinical, and animal research.